FindTrial
Sign In

The applications of genotype testing in the diagnosis of severe drug eruption

Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-CCC-14004398
Enrollment
Unknown
Registered
2014-03-06
Start date
2014-03-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug eruption

Interventions

Carbamazepine/Allopurinol sensitized SJS/TEN patients:Extraction DNA from subjects' peripheral blood and using PCR to genotype HLA-B loci.
Carbamazepine/Allopurinol non-sensitized SJS/TEN patients:Extraction DNA from subjects' peripheral blood and using PCR to genotype HLA-B loci.
Carbamazepine/Allopurinol sensitized eruptive patients:Extraction DNA from subjects' peripheral blood and using PCR to genotype HLA-B loci.
Normal individuals:Extraction DNA from subjects' peripheral blood and using PCR to genotype HLA-B loci.

Sponsors

Institute of Dermatology, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Males and females aged between 2 and 80 years; 2. Provide written informed consent and Willing and able to comply with all aspects of the protocol.

Exclusion criteria

Exclusion criteria: Patients with a history of blood coagulation dysfunction disorders

Design outcomes

Primary

MeasureTime frame
HLA-B *1502/580;—

Countries

China

Contacts

Public ContactBaoxi Wang

Institute of Dermatology, Chinese Academy of Medical Sciences

wangbx@ncstdlc.org+86 025-85478071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026